See below for the complete schedule for this year’s ACTRIMS-ECTRIMS Multiple Sclerosis conference in Boston, and stay tuned to Multiple Sclerosis News throughout the week for continuing coverage on breaking science and research news for MS. For the past few weeks, Multiple Sclerosis News Today has been following the lead-up…

During the 30th Congress of the European Committee for Research and Treatment in Multiple Sclerosis (ECTRIMS) taking place in Boston between September 10th and 13th, Genzyme, a Sanofi company, will present its multiple sclerosis (MS) pipeline with a new group of trial treatments for early development of MS.

Biogen Idec, one of the first true biotech companies specializing in products indicated for neurodegenerative diseases, hematologic conditions, and autoimmune disorders, is preparing to present over 90 poster presentations during this week’s 6th Joint ACTRIMS-ECTRIMS Meeting. The event is scheduled to take place from Wednesday, September 10th through Saturday the…

While multiple sclerosis is most typically associated with progressively declining physical ability, multiple sclerosis patients are often times affected by a number of physical and mental health comorbidities in addition to their worsening physical ability. This observation was highlighted by a group of researchers in Scotland led by Drs.

Those attending this week’s ACTRIMS-ECTRIMS convention set to take place on the 10th of September until the 13th in Boston, can expect Swiss pharmaceutical company Novartis to present promising findings on Gilenya (fingolimod) — the company’s leading oral formulation for relapsing-remitting multiple sclerosis (RRMS). In previously completed studies and clinical trials,…

A new study, entitled, “Intestinal barrier dysfunction develops at the onset of experimental autoimmune encephalomyelitis, and can be induced by adoptive transfer of auto-reactive T cells” conducted at University of Lund, Sweden, published on PlosOne by the research group of Dr. Shahram Lavasani in collaboration with…

A novel therapeutic from GeNeuro to treat multiple sclerosis showed promising results in a one-year, open-label extension phase 2a clinical trial. GeNeuro tested its first-in-class GNbAC1 monoclonal antibody in ten multiple sclerosis patients, nine of whom have primary or secondary progressive multiple sclerosis. “We are very excited by the…

A dynamic research team composed of doctors and scientists recently completed and published a study that sought to gain a better understanding of walking impairment, as it is manifested in patients living with multiple sclerosis (MS), a neurodegenerative disease wherein the impulse-conducting myelin sheath is attacked by the body’s own…

Researchers from the University of Bristol have found a way of convert the function of cells into protecting the body instead of destroying healthy tissue, in what could be an important breakthrough for the treatment of debilitating autoimmune diseases in which the immune system mistakenly attacks the body, like…

Novartis has announced that it will present new analyses and redefined treatment goals for multiple sclerosis (MS) at the 2014 Joint Americas and European Committees for Treatment and Research in Multiple Sclerosis Meeting (ACTRIMS-ECTRIMS), which is taking place in Boston, between September 10 and 13. Novartis claims to have…

In-vitro laboratory experiments using stem cells have long-since been the subject of debate between scientists and naturalists, but when it comes to developing effective methods to grow human cells and tissue for use in a potentially life-saving procedure or restoration of bodily function, researchers are increasingly more confident that…

The U.S. Food and Drug Administration (FDA) accepted the abbreviated new drug application (ANDA) for filing of a Glatiramer Acetate Injection for the treatment of patients with relapsing forms of multiple sclerosis (MS).

Yoga improves the quality of life of patients who suffer from multiple sclerosis, as recently concluded during a study of its benefits in increasing mental health, concentration, bladder control, walking, balance, motor coordination and vision, as well as in decreasing pain and fatigue. Researchers from Rutgers’ School of Health Related Professions…

As researchers continue to develop a clearer understanding of the underlying causes of multiple sclerosis (MS), it is becoming increasingly apparent that the future of treating the disease is likely to center on neural protection and a reversal of the demyelination process that strips away the critical insulation…

A diet high in salt can worsen multiple sclerosis (MS) symptoms, as well as increase the risks of neurological deterioration, according to an observational study led by Mauricio Farez, from the Universidad del Salvador in Buenos Aires, Argentina and recently published at the Journal of Neurology, Neurosurgery & Psychiatry, entitled, “Sodium intake is associated with…